114 results
Page 4 of 6
6-K
EX-99.1
wjq928zn0qw6eq
13 Jan 21
Current report (foreign)
4:00pm
6-K
EX-99.1
jxd6n0 r9fib
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
6-K
EX-99.1
2hyl8n 9fmvxcy
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.1
lsre83 f0
24 Nov 20
Current report (foreign)
6:03am
6-K
EX-99.1
cx0l7e 6d6d
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
EX-99.2
zlo g07865siv7za
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
EX-1.1
z54uvnppvx6srcr
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
2ctwh8sushin
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
EX-99.1
s6gsaq2tr8gh 94
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.3
jmi98mx7ps7ef0po6g
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.2
uqeb7w7 qxp8drbt
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.1
5ual1yl fgh
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
EX-99.1
fvx2qjoz7rj3dkew
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
EX-99.2
xvk4szth
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.3
1rl6s36hxgmj4j uynf
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
ff1e1vf5tz4h
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
rhv9uuh8fzl8 yds2z7
23 Mar 20
ObsEva Provides Update Related to COVID-19 Pandemic
4:00pm